E. Fowler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
E. Fowler has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Gil Yosipovitch
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miami Itch Center University of Miami Miller School of Medicine Miami Florida USA
1 shared publication J. Rosen
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, United States
1 shared publicationJ.C. Tang
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, United States
1 shared publication- Jashin J. Wu
University of Miami Miller School of Medicine
1 shared publication L. Strowd
Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, United States
1 shared publicationL.A. Nattkemper
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, United States
1 shared publication
Latest Publications
- 1 December 2020
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (12) , E842-E843
Immunohistochemistry analysis of itch and pain mediators in nonmelanoma skin cancer
Click on the article title to read more.
- 1 December 2020
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (12) , E842-E843
Immunohistochemistry analysis of itch and pain mediators in nonmelanoma skin cancer
Click on the article title to read more.
- 3 February 2020
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (7) , 1449-1456
Risk of tuberculosis reactivation during interleukin‐17 inhibitor therapy for psoriasis: a systematic review
Immunosuppressive therapies, effective in treating inflammatory disorders such as psoriasis, increase the risk of serious infections, such as tuberculosis (TB). For example, tumour necrosis factor (TNF)‐alpha inhibitors significantly increase the risk of TB reactivation in patients with latent TB infection (LTBI), which has led clinicians to routinely test for TB prior to initiation of these medications. This protocol has since extended to other, newer immunomodulatory therapies for psoriasis, such as interleukin (IL)‐17 inhibitors, including secukinumab, ixekizumab and brodalumab. We conducted a systematic review to examine whether there is any evidence that IL‐17 inhibitor therapy for psoriasis increases the risk of TB reactivation. Using PubMed and EMBASE, our literature search resulted in 139 total articles. After manually reviewing each article for the discussion of IL‐17 inhibitors for psoriasis, with data originating from clinical trials, and assessment for incidence of TB reactivation, 23 articles met the full inclusion criteria for our review. Overall, we found no cases of TB reactivation in patients treated with IL‐17 inhibitors for psoriasis. This suggests that IL‐17 inhibitors may be safely used in psoriasis patients with LTBI who receive appropriate LTBI treatment. However, long‐term real‐world studies are warranted to further evaluate this risk.
- 3 February 2020
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (7) , 1449-1456
Risk of tuberculosis reactivation during interleukin‐17 inhibitor therapy for psoriasis: a systematic review
Immunosuppressive therapies, effective in treating inflammatory disorders such as psoriasis, increase the risk of serious infections, such as tuberculosis (TB). For example, tumour necrosis factor (TNF)‐alpha inhibitors significantly increase the risk of TB reactivation in patients with latent TB infection (LTBI), which has led clinicians to routinely test for TB prior to initiation of these medications. This protocol has since extended to other, newer immunomodulatory therapies for psoriasis, such as interleukin (IL)‐17 inhibitors, including secukinumab, ixekizumab and brodalumab. We conducted a systematic review to examine whether there is any evidence that IL‐17 inhibitor therapy for psoriasis increases the risk of TB reactivation. Using PubMed and EMBASE, our literature search resulted in 139 total articles. After manually reviewing each article for the discussion of IL‐17 inhibitors for psoriasis, with data originating from clinical trials, and assessment for incidence of TB reactivation, 23 articles met the full inclusion criteria for our review. Overall, we found no cases of TB reactivation in patients treated with IL‐17 inhibitors for psoriasis. This suggests that IL‐17 inhibitors may be safely used in psoriasis patients with LTBI who receive appropriate LTBI treatment. However, long‐term real‐world studies are warranted to further evaluate this risk.